The estimated Net Worth of Anthony G. Quinn is at least $3.55 millió dollars as of 1 December 2023. Anthony Quinn owns over 88,495 units of Aeglea BioTherapeutics Inc stock worth over $1,062,825 and over the last 8 years he sold AGLE stock worth over $0. In addition, he makes $2,482,780 as President and Chief Executive Officer és Director at Aeglea BioTherapeutics Inc.
Sign up
Anthony Quinn AGLE stock SEC Form 4 insiders trading
Anthony has made over 17 trades of the Aeglea BioTherapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 88,495 units of AGLE stock worth $124,778 on 1 December 2023.
The largest trade he's ever made was exercising 171,890 units of Aeglea BioTherapeutics Inc stock on 7 December 2018 worth over $751,159. On average, Anthony trades about 25,737 units every 80 days since 2016. As of 1 December 2023 he still owns at least 88,495 units of Aeglea BioTherapeutics Inc stock.
You can see the complete history of Anthony Quinn stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Anthony Quinn biography
Dr. Anthony G. Quinn M.D. Ph.D. serves as President and Chief Executive Officer, Director of the Company. Dr. Quinn previously served as our interim Chief Medical Officer between April 2017 and July 2017 and served as our interim Chief Executive Officer between July 2017 and July 2018. Since October 2015, Dr. Quinn has worked as a private consultant for IDBioPharm Consulting LLC. From August 2009 to June 2015, Dr. Quinn served as Head of Research & Development and Chief Medical Officer initially at the Senior Vice President level and subsequently at the Executive Vice President level for Synageva BioPharma Corp., a publicly traded biopharmaceutical company that was acquired by Alexion Pharmaceuticals, Inc. in June 2015. Following the acquisition, Dr. Quinn worked for Alexion Pharmaceuticals from June 2015 to September 2015. Dr. Quinn currently serves on the boards of directors at Kaleido Biosciences, Inc and a private company. Dr. Quinn received a B.MSc in General Pathology and a M.B Ch.B in Medicine from the University of Dundee. Dr. Quinn later earned a Ph.D. in Cancer Research from the University of Newcastle upon Tyne. Quinn is qualified to serve on our board of directors because of his medical and clinical experience in the biopharmaceutical industry, including the development of therapeutics for rare diseases.
What is the salary of Anthony Quinn?
As the President and Chief Executive Officer és Director of Aeglea BioTherapeutics Inc, the total compensation of Anthony Quinn at Aeglea BioTherapeutics Inc is $2,482,780. There are no executives at Aeglea BioTherapeutics Inc getting paid more.
How old is Anthony Quinn?
Anthony Quinn is 58, he's been the President and Chief Executive Officer és Director of Aeglea BioTherapeutics Inc since 2019. There are 3 older and 12 younger executives at Aeglea BioTherapeutics Inc. The oldest executive at Aeglea BioTherapeutics Inc is V. Bryan Lawlis, 68, who is the Independent Director.
What's Anthony Quinn's mailing address?
Anthony's mailing address filed with the SEC is C/O GENERATION BIO CO., 301 BINNEY ST, , CAMBRIDGE, MA, 02142.
Insiders trading at Aeglea BioTherapeutics Inc
Over the last 8 years, insiders at Aeglea BioTherapeutics Inc have traded over $1,425,674 worth of Aeglea BioTherapeutics Inc stock and bought 1,931,829 units worth $12,152,489 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Bioventures Ltd Novartis Ag... és Advisors Llc Orbi Med Capit.... On average, Aeglea BioTherapeutics Inc executives and independent directors trade stock every 70 days with the average trade being worth of $864,564. The most recent stock trade was executed by Marcio Souza on 25 August 2022, trading 90,000 units of AGLE stock currently worth $50,400.
What does Aeglea BioTherapeutics Inc do?
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f
What does Aeglea BioTherapeutics Inc's logo look like?
Complete history of Anthony Quinn stock trades at Aeglea BioTherapeutics Inc, Kaleido Biosciences Inc és Generation Bio Co
Aeglea BioTherapeutics Inc executives and stock owners
Aeglea BioTherapeutics Inc executives and other stock owners filed with the SEC include:
-
Anthony Quinn,
President and Chief Executive Officer, Director -
Leslie Sloan,
Chief Operating Officer -
Charles York,
Chief Financial Officer, Vice President -
Dr. Anthony G. Quinn M.D., M.B Ch.B., Ph.D., FRCP,
Pres, CEO & Director -
Dr. Leslie S. Sloan Ph.D.,
Chief Operating Officer -
Russell Cox,
Independent Chairman of the board -
Sandesh Mahatme,
Independent Director -
Suzanne Bruhn,
Independent Director -
Ivana Magovcevic-Liebisch,
Independent Director -
V. Bryan Lawlis,
Independent Director -
Armen Shanafelt,
Independent Director -
Joey Perrone,
Director, Finance & Investor Relations -
Ravi Rao,
Chief Medical Officer -
Michael Hanley,
Chief Commercial Officer -
Michael C. Hanley M.B.A.,
Chief Commercial Officer -
Eugene Sackett,
VP of HR -
Kelly Boothe Ph.D.,
Sr. Director of Corp. Communications -
James Paul Kastenmayer J.D., Ph.D.,
Gen. Counsel -
Cortney Caudill M.B.A.,
Sr. VP of Technical Operations -
Steven Weber,
VP, Principal Accounting Officer & Corp. Controller -
Jonathan D. Alspaugh M.B.A.,
Chief Financial Officer -
Aaron Schuchart,
Chief Business Officer -
Joseph E Tyler,
VP, Manufacturing -
Scott W Rowlinson,
VP, Research -
David George Lowe,
CEO and President -
Henry Hebel,
VP, Product Development -
Advisors Llc Orbi Med Capit...,
-
George Georgiou,
Director -
Lilly & Co Eli,
10% owner -
Bioventures Ltd Novartis Ag...,
-
Laurie Stelzer,
-
Jeffrey W. Albers,
-
Cameron Turtle,
Chief Executive Officer -
Funds Management Llc Fairmo...,
-
Heidy King Jones,
See Remarks -
Scott L Burrows,
Chief Financial Officer -
James Wooldridge,
Chief Medical Officer -
Linda L Neuman,
Chief Medical Officer -
Alison Frances Lawton,
Director -
Marcio Souza,
Director -
Steven Weber,
VP, Controller&Princ Acctg Off -
Bros. Advisors Lp667, L.P.B...,
-
Hunter C Smith,
Director -
James Paul Kastenmayer,
General Counsel -
Jeff Marc Goldberg,
President and CEO -
Jonathan Alspaugh,
President and CFO